Seminari di Ematologia Oncologica - Società Italiana di Ematologia

42 Seminari di Ematologia Oncologica
31. Solal-Céligny P, Roy P, Colombat P, White J,
Armitage JO, Arranz-Saez R, et al. Follicular lymphoma
international prognostic index. Blood. 2004;
104: 1258-65.
32. Federico M, Bellei M, Marcheselli L, Luminari S,
Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma
international prognostic index 2: a new prognostic
index for follicular lymphoma developed by the international
follicular lymphoma prognostic factor project.
J Clin Oncol. 2009; 27: 4555-62.
33. Møller MB, Pedersen NT, Christensen BE. Mantle cell
lymphoma: prognostic capacity of the Follicular
Lymphoma International Prognostic Index. Br J
Haematol. 2006; 133: 43-9.
34. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van
Hoof A, Kluin-Nelemans HC, et al. A new prognostic
index (MIPI) for patients with advanced-stage mantle
cell lymphoma. Blood. 2008; 111: 558-65.
35. Weisenburger DD, Vose JM, Greiner TC, Lynch JC,
Chan WC, Bierman PJ, et al. Mantle cell lymphoma.
A clinicopathologic study of 68 cases from the
Nebraska Lymphoma Study Group. Am J Hematol.
2000; 64: 190-6.
36. Räty R, Franssila K, Joensuu H, Teerenhovi L,
Elonen E. Ki-67 expression level, histological subtype,
and the International Prognostic Index as outcome
predictors in mantle cell lymphoma. Eur J Haematol.
2002; 69: 11-20.
37. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E,
Sametti S, et al. Long-term follow-up of indolent lymphoma
patients treated with high-dose sequential
chemotherapy and autografting: evidence that durable
molecular and clinical remission frequently can be
attained only in follicular subtypes. J Clin Oncol. 2004;
22: 1460-8.
38. Pott C, Schrader C, Gesk S, Harder L, Tiemann M,
Raff T, et al. Quantitative assessment of molecular
remission after high-dose therapy with autologous
stem cell transplantation predicts long-term remission
in mantle cell lymphoma. Blood. 2006; 107: 2271-8.
39. Andersen NS, Pedersen LB, Laurell A, Elonen E,
Kolstad A, Boesen AM, et al. Pre-emptive treatment
with rituximab of molecular relapse after autologous
stem cell transplantation in mantle cell lymphoma. J
Clin Oncol. 2009; 27: 4365-70.
40. Pott C, Hoster E, Delfau-Larue MH, Beldjord K,
Böttcher S, Asnafi V, et al. Molecular remission is an
independent predictor of clinical outcome in patients
with mantle cell lymphoma after combined
immunochemotherapy: a European MCL intergroup
study. Blood. 2010; 115: 3215-23.
41. Magni M, Di Nicola M, Devizzi L, Matteucci P,
Lombardi F, Gandola L, et al. Successful in vivo purging
of CD34-containing peripheral blood harvests in
mantle cell and indolent lymphoma: evidence for a
role of both chemotherapy and rituximab infusion.
Blood. 2000; 96: 864-9.
42. Brugger W, Hirsch J, Grünebach F, Repp R, Brossart
P, Vogel W, et al. Rituximab consolidation after highdose
chemotherapy and autologous blood stem cell
transplantation in follicular and mantle cell lymphoma:
a prospective, multicenter phase II study. Ann Oncol.
2004; 15: 1691-8.
43. Geisler CH, Kolstad A, Laurell A, Andersen NS,
Pedersen LB, Jerkeman M, et al. Long-term progression-free
survival of mantle cell lymphoma after intensive
front-line immunochemotherapy with in vivopurged
stem cell rescue: a nonrandomized phase 2
multicenter study by the Nordic Lymphoma Group.
Blood. 2008; 112: 2687-93.
44. Andersen NS, Donovan JW, Borus JS, Poor CM,
Neuberg D, Aster JC, et al. Failure of immunologic
purging in mantle cell lymphoma assessed by polymerase
chain reaction detection of minimal residual
disease. Blood. 1997; 90: 4212-21.
45. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-
Stella C, Pilotti S, et al. Long-term remission in mantle
cell lymphoma following high-dose sequential
chemotherapy and in vivo rituximab-purged stem cell
autografting (R-HDS regimen). Blood. 2003; 102:
749-55.
46. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi
D, Ricca I, et al. Rituximab induces effective clearance
of minimal residual disease in molecular relapses
of mantle cell lymphoma. Biol Blood Marrow
Transplant. 2006; 12: 1270-6.
47. Martin P, Chadburn A, Christos P, Furman R, Ruan
J, Joyce MA, et al. Intensive treatment strategies may
not provide superior outcomes in mantle cell lymphoma:
overall survival exceeding 7 years with standard
therapies. Ann Oncol. 2008; 19: 1327-30.
48. Martin P, Chadburn A, Christos P, Weil K, Furman
RR, Ruan J, et al. Outcome of deferred initial therapy
in mantle-cell lymphoma. J Clin Oncol. 2009;
27: 1209-13.
49. Oken MM, Creech RH, Tormey DC, Horton J, Davis
TE, McFadden ET, et al. Toxicity and response criteria
of the Eastern Cooperative Oncology Group. Am
J Clin Oncol. 1982; 5: 649-55.
50. Balducci L, Yates J. General guidelines for the management
of older patients with cancer. Oncology.
2000; 14: 221-7.
51. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen
U, Metzner B, et al. Immunochemotherapy with rituximab
and cyclophosphamide, doxorubicin, vincristine,
and prednisone significantly improves
response and time to treatment failure, but not longterm
outcome in patients with previously untreated
mantle cell lymphoma: results of a prospective
randomized trial of the German Low Grade
Lymphoma Study Group (GLSG). J Clin Oncol.
2005; 23: 1984-92.
52. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse
N, Thieblemont C, et al. Alternating courses of 3x